Qing Tang

This inventor holds 47 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 16 EPO patents, primarily in Protein Kinase Inhibitors. Top assignees: Vertex Pharmaceuticals, Inc., Merck Patent Gmbh, Cellarity, Inc.. Active years: 2003-2026.

USPTO Granted Patents = 47 (Patent Applications = 12)

% Patents Active = 63.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 16 (Patent Applications = 22)

Average Co-Inventor Count = 7.8

ph-index = 15

Forward Citations = 692(Granted Patents)

Location History:

Cambridge, MA (US) (2003 - 2007)
Winchester, MA (US) (2008)
Acton, MA (US) (2007 - 2023)
Boxborough, MA (US) (2023 - 2024)

Company Filing History:

45 out of 1,167

Vertex Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Alpha-1-Antitrypsin Modulators

DNA-PK Inhibitors

ERK Protein Kinase Inhibitors

Antiproliferation Compounds

c-MET Inhibitors

Serine Protease Inhibitors

Heteroaryl Compounds

Substituted Quinoxalines

Prodrugs

Pyrrole Inhibitors

Pyrazole Compositions

Selective Inhibitors

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662471 - 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2026-06-23),

2. 12624028 - 1H-pyrazolo[4,3-G]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2026-05-12),

3. 12502376 - Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2025-12-23),

4. 12473285 - DCN-1 modulating compounds and methods of use thereof (2025-11-18),

5. 12435087 - Modulators of DCN-1 and methods of use thereof (2025-10-07),

6. 12331057 - Modulators of alpha-1 antitrypsin (2025-06-17),

7. 12251387 - Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors (2025-03-18),

8. 12195453 - Antiproliferation compounds and uses thereof (2025-01-14),

9. 12005127 - DNA-PK inhibitors (2024-06-11),

10. 11884672 - Modulators of alpha-1 antitrypsin (2024-01-30),

11. 11813267 - DNA-PK inhibitors (2023-11-14),

12. RE49500 - Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto (2023-04-24),

13. 11623924 - Modulators of alpha-1 antitrypsin (2023-04-11),

14. 11440907 - Antiproliferation compounds and uses thereof (2022-09-13),

15. 10973830 - Substituted quinoxaline DNA-PK inhibitors (2021-04-13),

Title: Inventor Qing Tang: Pioneering Innovations in Acton

Introduction: Qing Tang, a visionary inventor based in Acton, MA, is renowned for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Qing Tang holds several patents in the areas of artificial intelligence, renewable energy, and sustainable technologies, showcasing her commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Qing Tang has worked with leading tech companies and research institutions, spearheading projects that have revolutionized the industry.

Collaborations: Throughout her career, Qing Tang has collaborated with top researchers, engineers, and scientists, fostering a culture of innovation and excellence in all her projects.

Conclusion: Qing Tang's passion for innovation and her relentless pursuit of technological advancement continue to inspire the next generation of inventors and entrepreneurs.